For healthcare professionals only

News Shortcuts from other journals

Pexelizumab fails to improve outcomes after heart attack

BMJ 2007; 334 doi: (Published 11 January 2007) Cite this as: BMJ 2007;334:66

The monoclonal antibody pexelizumab was designed to suppress the damaging inflammatory cascade that follows reperfusion treatments for heart attack. Early trials produced promising results, so researchers were disappointed when pexelizumab failed to save lives or improve outcomes for 5745 patients who had …

View Full Text

Log in

Log in through your institution


* For online subscription